Emanuele Marzetti1, Matteo Cesari2, Riccardo Calvani3, Jérôme Msihid4, Matteo Tosato1, Leocadio Rodriguez-Mañas5, Fabrizia Lattanzio6, Antonio Cherubini7, Raphaël Bejuit4, Mauro Di Bari8, Marcello Maggio9, Bruno Vellas10, Thierry Dantoine11, Alfonso J Cruz-Jentoft12, Cornel C Sieber13, Ellen Freiberger13, Anna Skalska14, Tomasz Grodzicki14, Alan J Sinclair15, Eva Topinkova16, Ingrid Rýznarová17, Timo Strandberg18, Annemie M W J Schols19, Jos M G A Schols20, Regina Roller-Wirnsberger21, Pálmi V Jónsson22, Alfons Ramel22, Susanna Del Signore23, Marco Pahor24, Ronenn Roubenoff25, Roberto Bernabei1, Francesco Landi1. 1. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 2. Department of Clinical Sciences and Community Health, University of Milan, Italy; Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 3. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: riccardo.calvani@gmail.com. 4. Sanofi R&D, Chilly-Mazarin, Paris, France. 5. Service of Geriatrics, Getafe University Hospital, Madrid, Spain. 6. Scientific Direction, IRCCS INRCA, Ancona, Italy. 7. Geriatria, Accettazione Geriatrica e Centro di Ricerca per l'Invecchiamento, IRCCS INRCA, Ancona, Italy. 8. Research Unit of Medicine of Aging, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Division of Geriatric Cardiology and Medicine, Department of Geriatrics and Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 9. Department of Geriatric Rehabilitation, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy. 10. Gérontopôle, University Hospital of Toulouse, Toulouse, France. 11. University Hospital of Limoges, Limoges, France. 12. Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. 13. Institute for Biomedicine of Aging, Friedrich-Alexander-University, Nuremberg, Germany. 14. Department of Internal Medicine and Gerontology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland. 15. Foundation for Diabetes Research in Older People, Diabetes Frail Limited, Worcestershire, UK. 16. Department of Geriatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic. 17. Geriatric Department, Silesians Hospital, Opava, Czech Republic. 18. University of Helsinki, Clinicum, Helsinki, Finland; Helsinki University Hospital, Medicine and Rehabilitation, Helsinki, Finland; University of Oulu, Center for Life Course Health Research, Oulu, Finland. 19. Department of Respiratory Medicine, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Center, Maastricht, the Netherlands. 20. Department of Health Services Research, Maastricht University Medical Center, Maastricht, the Netherlands. 21. Department of Internal Medicine, Medical University of Graz, Graz, Austria. 22. Department of Geriatrics, Faculty of Medicine, Landspitali University Hospital, University of Iceland, Reykjavik, Iceland. 23. BlueCompanion Ltd., London, UK; Biophytis, Paris, France. 24. Department of Aging and Geriatric Research, Institute on Aging, University of Florida, Gainesville, FL, USA. 25. Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Abstract
BACKGROUND: The ongoing "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)" randomized controlled trial (RCT) is testing the efficacy of a multicomponent intervention in the prevention of mobility disability in older adults with physical frailty & sarcopenia (PF&S). Here, we describe the procedures followed for PF&S case finding and screening of candidate participants for the SPRINTT RCT. We also illustrate the main demographic and clinical characteristics of eligible screenees. METHODS: The identification of PF&S was based on the co-occurrence of three defining elements: (1) reduced physical performance (defined as a score on the Short Physical Performance Battery between 3 and 9); (2) low muscle mass according to the criteria released by the Foundation for the National Institutes of Health; and (3) absence of mobility disability (defined as ability to complete the 400-m walk test in 15 min). SPRINTT was advertised through a variety of means. Site-specific case finding strategies were developed to accommodate the variability across centers in catchment area characteristics and access to the target population. A quick "participant profiling" questionnaire was devised to facilitate PF&S case finding. RESULTS: During approximately 22 months, 12,358 prescreening interviews were completed in 17 SPRINTT sites resulting in 6710 clinic screening visits. Eventually, 1566 candidates were found to be eligible for participating in the SPRINTT RCT. Eligible screenees showed substantial physical function impairment and comorbidity burden. In most centers, project advertisement through mass media was the most rewarding case finding strategy. CONCLUSION:PF&S case finding in the community is a challenging, but feasible task. Although largely autonomous in daily life activities, older adults with PF&S suffer from significant functional impairment and comorbidity. This subset of the older population is therefore at high risk for disability and other negative health-related events. Key strategies to consider for successfully intercepting at-risk older adults should focus on mass communication methods.
RCT Entities:
BACKGROUND: The ongoing "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)" randomized controlled trial (RCT) is testing the efficacy of a multicomponent intervention in the prevention of mobility disability in older adults with physical frailty & sarcopenia (PF&S). Here, we describe the procedures followed for PF&S case finding and screening of candidate participants for the SPRINTT RCT. We also illustrate the main demographic and clinical characteristics of eligible screenees. METHODS: The identification of PF&S was based on the co-occurrence of three defining elements: (1) reduced physical performance (defined as a score on the Short Physical Performance Battery between 3 and 9); (2) low muscle mass according to the criteria released by the Foundation for the National Institutes of Health; and (3) absence of mobility disability (defined as ability to complete the 400-m walk test in 15 min). SPRINTT was advertised through a variety of means. Site-specific case finding strategies were developed to accommodate the variability across centers in catchment area characteristics and access to the target population. A quick "participant profiling" questionnaire was devised to facilitate PF&S case finding. RESULTS: During approximately 22 months, 12,358 prescreening interviews were completed in 17 SPRINTT sites resulting in 6710 clinic screening visits. Eventually, 1566 candidates were found to be eligible for participating in the SPRINTT RCT. Eligible screenees showed substantial physical function impairment and comorbidity burden. In most centers, project advertisement through mass media was the most rewarding case finding strategy. CONCLUSION:PF&S case finding in the community is a challenging, but feasible task. Although largely autonomous in daily life activities, older adults with PF&S suffer from significant functional impairment and comorbidity. This subset of the older population is therefore at high risk for disability and other negative health-related events. Key strategies to consider for successfully intercepting at-risk older adults should focus on mass communication methods.
Authors: Hélio José Coelho-Júnior; Marco Carlos Uchida; Anna Picca; Roberto Bernabei; Francesco Landi; Riccardo Calvani; Matteo Cesari; Emanuele Marzetti Journal: Aging Clin Exp Res Date: 2021-02-15 Impact factor: 3.636
Authors: Yari Longobucco; Sebastian Krumpoch; Fulvio Lauretani; Valentina Angileri; Cornel Sieber; Emanuele Marzetti; Riccardo Calvani; Antonio Cherubini; Francesco Landi; Roberto Bernabei; Ellen Freiberger; Marcello Maggio Journal: Aging Clin Exp Res Date: 2022-02-08 Impact factor: 4.481
Authors: Yari Longobucco; Chiara Benedetti; Sara Tagliaferri; Vincenza Valentina Angileri; Elisa Adorni; Michele Pessina; Luna Zerbinati; Lorenzo Cicala; Giovanna Pelà; Vittoria Giacomini; Mirca Barbolini; Fulvio Lauretani; Marcello Giuseppe Maggio Journal: Acta Biomed Date: 2019-05-23